Understanding chronic inflammatory and neuropathic pain

Annals of the New York Academy of Sciences

Volumn 1255, Issue 1, 2012, Pages 30-44

  Hughes, Jane P ^a   Chessell, Iain ^a   Malamut, Richard ^b   Perkins, Martin ^b   Bačkonja, Miroslav ^c,s   Baron, Ralf ^d   Farrar, John T ^e   Field, Mark J ^f   Gereau, Robert W ^g   Gilron, Ian ^h   Mcmahon, Stephen B ⁱ   Porreca, Frank ^j   Rappaport, Bob A ^k,t   Rice, Frank ^l,u   Richman, Laura K ^a   Segerdahl, Märta ^m   Seminowicz, David A ⁿ   Watkins, Linda R ^o   Waxman, Stephen G ^p,v   Wiech, Katja ^q   Woolf, Clifford ^r   more..

^a MEDIMMUNE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c LifeTree Research   (United States)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f GRÜNENTHAL GMBH   (Germany)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h QUEEN S UNIVERSITY   (Canada)

ⁱ KING'S COLLEGE LONDON   (United Kingdom)

^j UNIVERSITY OF ARIZONA   (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l Integrated Tissue Dynamics LLC   (United States)

^m ASTRAZENECA R AND D   (Sweden)

ⁿ UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^o UNIVERSITY OF COLORADO   (United States)

^p YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF OXFORD   (United Kingdom)

^r BOSTON CHILDREN S HOSPITAL   (United States)

^s UNIVERSITY OF WISCONSIN MADISON   (United States)

^t Addiction Products   (United States)

^u ALBANY MEDICAL COLLEGE   (United States)

^v VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; CHEMOKINE; CYCLOOXYGENASE 2; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; METABOTROPIC RECEPTOR AGONIST; MONOCLONAL ANTIBODY; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTANOID; RESINIFERATOXIN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT;

ANALGESIC ACTIVITY; CHRONIC INFLAMMATION; CHRONIC PAIN; CLINICAL PRACTICE; CONFERENCE PAPER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE MUTATION; GOVERNMENT; HUMAN; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROPATHIC PAIN; NONHUMAN; PAIN;

EID: 84860621032     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06561.x     Document Type: Conference Paper

References (54)

1. Costigan, M., J. Scholz & C.J. Woolf 2009. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annual Review of Neuroscience 32: 1-32.
2. Neely, G.G., A. Hess, M. Costigan, A.C. Keene, et al 2010. A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell 143: 628-638
3. Woolf, C.J. 2010. Overcoming obstacles to developing new analgesics. Nat Med 16: 1241-1247.
4. Dawes, J.M., M. Calvo, J.R. Perkins, et al 2011. CXCL5 mediates UVB irradiation-induced pain. Sci Transl Med. 3(90): 90ra60.
5. Daugherty, A.L. & R.J. Mrsny 2006. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Del. Rev. 58: 686-706.
6. Filpula, D. 2007. Antibody engineering and modification technologies. Biomol. Eng. 24: 201-215.
7. Bacher, M., C. Depboylu, Y. Du, C. Noelker, et al 2009. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 449: 240-245.
8. Boado, R.J., Y. Zhang, Y. Zhang, et al 2007. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation. Bioconjugate Chem. 18: 447-455.
9. Waxman, S.G. 2010. Polymorphisms in ion channel genes: emerging roles in pain. Brain 133: 2514-2518.
10. Dib-Hajj, S.D., T.R. Cummins, J.A. Black & S.G. Waxman 2010. Sodium channels in normal and pathological pain. Ann Rev Neurosci. 33: 325-347.
11. Dib-Hajj, S.D., A.M. Rush, T.R. Cummins, et al 2005. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain 128: 1847-1854.
12. v1.7 mutation producing carbamazepine-responsive erythromelalgia. Ann Neurol 65: 733-741.
13. Campbell, J.N. & R.A. Meyer 2006. Mechanisms of neuropathic pain. Neuron. 52: 77-92.
14. Rice, A.S. et al 2008. Animal models and the prediction of efficacy in clinical trials of analgesic drugs: a critical appraisal and call for uniform reporting standards. Pain 139: 243-247.
15. Vierck, C.J., P.T. Hansson & R.P. Yezierski 2008. Clinical and pre-clinical pain assessment: are we measuring the same thing? Pain 135: 7-10.
16. King, T. et al 2009. Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci. 12: 1364-1366.
17. King, T., et al 2011. Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity. Pain.
18. Qu, C. et al 2011. Lesion of the rostral anterior cingulate cortex eliminates the aversiveness of spontaneous neuropathic pain following partial or complete axotomy. Pain. in press.
19. Johansen, J.P., H.L. Fields & B.H. Manning 2001. The affective component of pain in rodents: direct evidence for a contribution of the anterior cingulate cortex. Proceedings of the National Academy of Sciences of the United States of America 98: 8077-8082.
20. LaBuda, C.J. & P.N. Fuchs 2000. A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats. Exp Neurol. 163: 490-494.
21. Burgess, S.E. et al 2002. Time-dependent descending facilitation from the rostral ventromedial medulla maintains, but does not initiate, neuropathic pain. J. Neurosci. 22: 5129-5136.
22. Devor, M. 2009. Ectopic discharge in Abeta afferents as a source of neuropathic pain. Exp. Brain Res. 196: 115-128.
23. Ringkamp, M. & R.A. Meyer 2005. Injured versus uninjured afferents: Who is to blame for neuropathic pain? Anesthesiology 103: 221-223.
24. Gracely, R.H., S.A. Lynch & G.J. Bennett 1992. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 51: 175-194.
25. Devor, M. 1991. Sensory basis of autotomy in rats. Pain 45: 109-110.
26. Rodin, B.E. & L. Kruger 1984. Deafferentation in animals as a model for the study of pain: an alternative hypothesis. Brain Res. 319: 213-228.
27. Seminowicz, D.A., A.L. Laferriere, M. Millecamps, et al 2009. MRI structural brain changes associated with sensory and emotional function in a rat model of long-term neuropathic pain. Neuroimage 47: 1007-1014.
28. Rodriguez-Raecke, R., A. Niemeier, K. Ihle, et al 2009. Brain Gray Matter Decrease in Chronic Pain Is the Consequence and Not the Cause of Pain. J. Neurosci. 29: 13746-13750.
29. Obermann, M., K. Nebel, C. Schumann, et al 2009. Gray matter changes related to chronic posttraumatic headache. Neurology 73: 978-983.
30. Gwilym, S.E., N. Fillipini, G. Douaud, et al 2010. Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty; a longitudinal voxel-based-morphometric study. Arthritis Rheum.
31. Seminowicz, D.A., T.H. Wideman, L. Naso, et al 2011. Effective Treatment of Chronic Low Back Pain in Humans Reverses Abnormal Brain Anatomy and Function. The Journal of Neuroscience 31: 7540-7550.
32. Pereira, F., T. Mitchell & M. Botvinick 2009. Machine learning classifiers and fMRI: A tutorial overview. Neuroimage 45: S199-S209.
33. Marquand, A., M. Howard, M. Brammer, et al 2010. Quantitative prediction of subjective pain intensity from whole-brain fMRI data using Gaussian processes. Neuroimage 49: 2178-2189.
34. Prato, M., S. Favilla, L. Zanni, et al 2011. A regularization algorithm for decoding perceptual temporal profiles from fMRI data. Neuroimage 56: 258-267.
35. Owen, D.G., Y. Bureau, A.W. Thomas, et al 2008. Quantification of pain-induced changes in cerebral blood flow by perfusion MRI. Pain 136: 85-96.
36. Howard, M.A., K. Krause, N. Khawaja, et al 2011. Beyond patient reported pain: perfusion magnetic resonance imaging demonstrates reproducible cerebral representation of ongoing post-surgical pain. PLoS One 6: e17096.
37. Baron R., A. Binder & G. Wasner 2010. Neuropathic pain--diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 9: 807-819
38. Jensen T.S. & R. Baron 2003. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 102: 1-8.
39. Maier, C., R. Baron, et al 2010. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150: 439-450
40. Baron, R., T.R. Tölle, U. Gockel, et al 2009. A cross sectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 146: 34-40
41. Dworkin, R.H., D.C. Turk, S. Peirce-Sandner, et al 2010. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149(2): 177-193. PubMed PMID: 20207481.
42. Sindrup, S.H., L.F. Gram, K. Brøsen, et al 1990. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42(2): 135-144. PubMed PMID: 2147235.
43. Rowbotham, M.C., L. Twilling, P.S. Davies, et al 2003. Oral opioid therapy for chronic peripheral and central neuropathic pain. N. Engl. J. Med. 348(13): 1223-1232. PubMed PMID: 12660386.
44. Irving, G.A., M.M. Backonja, E. Dunteman, et al 2011. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 12(1): 99-109. PubMed PMID: 21087403.
45. Gilron, I., J.M. Bailey, D. Tu, et al 2005. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352(13): 1324-1334. PubMed PMID: 15800228.
46. Woolf, C.J. & M.B. Max 2001. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 95(1): 241-249. PubMed PMID: 11465563.
47. Wallace, M.S., M. Rowbotham, G.J. Bennett, et al 2002. A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J. Pain 3(3): 227-233. PubMed PMID: 14622777.
48. Dworkin, R.H., D.C. Turk, N.P. Katz, et al 2011. Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION. Pain 152(3 Suppl): S107-S115. Epub 2010 Dec 9. PubMed PMID: 21145657.
49. Turk, D.C., R.H. Dworkin, R.R. Allen, et al 2003. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 106(3): 337-345. PubMed PMID: 14659516.
50. Dworkin, R.H., D.C. Turk, J.T. Farrar, et al 2005. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1-2): 9-19. PubMed PMID: 15621359.
51. Senn, S. Cross-Over Trials in Clinical Research. Chichester, John Wiley, 1993.
52. Gilron, I. & M.P. Jensen 2011. Clinical trial methodology of pain treatment studies: selection and measurement of self-report primary outcomes for efficacy. Reg Anesth Pain Med. 36(4): 374-381. PubMed PMID: 21610560.
53. Dworkin, R.H., D.C. Turk, S. Peirce-Sandner, et al 2010. Placebo and treatment group responses in postherpetic neuralgia vs. painful diabetic peripheral neuropathy clinical trials in the REPORT database. Pain 150(1): 12-16. PubMed PMID: 20202753.
54. Rappaport, B.A., I. Cerny & W.R. Sanhai 2010. ACTION on the prevention of chronic pain after surgery: public-private partnerships, the future of analgesic drug development. Anesthesiology 112(3): 509-10. PubMed PMID: 20124974.